FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:UVRAG-RRAS2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: UVRAG-RRAS2
FusionPDB ID: 97812
FusionGDB2.0 ID: 97812
HgeneTgene
Gene symbol

UVRAG

RRAS2

Gene ID

7405

22800

Gene nameUV radiation resistance associatedRAS related 2
SynonymsDHTX|VPS38|p63NS12|TC21
Cytomap

11q13.5

11p15.2

Type of geneprotein-codingprotein-coding
DescriptionUV radiation resistance-associated gene proteinbeclin 1 binding proteindisrupted in heterotaxyras-related protein R-Ras2ras-like protein TC21related RAS viral (r-ras) oncogene homolog 2teratocarcinoma oncogene
Modification date2020031320200315
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000356136, ENST00000525872, 
ENST00000528420, ENST00000531818, 
ENST00000532130, ENST00000533454, 
ENST00000538870, ENST00000539288, 
ENST00000256196, ENST00000526063, 
ENST00000529237, ENST00000532814, 
ENST00000534746, ENST00000414023, 
ENST00000537760, ENST00000545643, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score41 X 18 X 15=110705 X 2 X 5=50
# samples 495
** MAII scorelog2(49/11070*10)=-4.49772966266634
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/50*10)=0
Fusion gene context

PubMed: UVRAG [Title/Abstract] AND RRAS2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: UVRAG [Title/Abstract] AND RRAS2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)UVRAG(75526569)-RRAS2(14317401), # samples:1
Anticipated loss of major functional domain due to fusion event.UVRAG-RRAS2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
UVRAG-RRAS2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
UVRAG-RRAS2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
UVRAG-RRAS2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneUVRAG

GO:0071900

regulation of protein serine/threonine kinase activity

22542840

HgeneUVRAG

GO:0097352

autophagosome maturation

28306502

HgeneUVRAG

GO:0097680

double-strand break repair via classical nonhomologous end joining

22542840



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:75526569/chr11:14317401)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across UVRAG (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across RRAS2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000356136UVRAGchr1175526569+ENST00000545643RRAS2chr1114317401-2276358153548131
ENST00000356136UVRAGchr1175526569+ENST00000537760RRAS2chr1114317401-2276358163864233
ENST00000356136UVRAGchr1175526569+ENST00000414023RRAS2chr1114317401-2242358299868189

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000356136ENST00000545643UVRAGchr1175526569+RRAS2chr1114317401-0.823924840.17607516
ENST00000356136ENST00000537760UVRAGchr1175526569+RRAS2chr1114317401-0.0005096660.99949026
ENST00000356136ENST00000414023UVRAGchr1175526569+RRAS2chr1114317401-0.0012635120.99873644

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for UVRAG-RRAS2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
UVRAGchr1175526569RRAS2chr111431740135820PRGPCMWSCRLSRQSYFVTDYDPTIE
UVRAGchr1175526569RRAS2chr111431740135864SAARALHVELPSQQSYFVTDYDPTIE

Top

Potential FusionNeoAntigen Information of UVRAG-RRAS2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
UVRAG-RRAS2_75526569_14317401.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:02ELPSQQSY0.86190.8714816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:08LPSQQSYF0.81190.6199917
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:01ELPSQQSY0.59510.7914816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:01RQSYFVTDY0.99950.61211221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:04CRLSRQSYF0.99940.6309817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:01QQSYFVTDY0.99860.59831221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:03VELPSQQSY0.99640.8402716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:01VELPSQQSY0.99130.865716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-A02:13RLSRQSYFV0.98740.5142918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:25RQSYFVTDY0.97180.69741221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:25QQSYFVTDY0.95680.73641221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:01VELPSQQSY0.95120.854716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:03LPSQQSYFV0.94860.7245918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:02LPSQQSYFV0.94360.7534918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:04LPSQQSYFV0.94360.7534918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:02QQSYFVTDY0.91420.77251221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:25VELPSQQSY0.79160.871716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:02VELPSQQSY0.68640.8771716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:03VELPSQQSY0.39350.689716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B45:01VELPSQQSY0.36620.7636716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:18VELPSQQSY0.26550.6312716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B13:02RLSRQSYFV0.16840.5106918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B50:01VELPSQQSY0.08780.7102716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:05SRQSYFVTDY0.99970.77691121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:01SQQSYFVTDY0.99910.56551121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:03VELPSQQSYF0.99490.8766717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:02SCRLSRQSYF0.99390.5101717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:04SCRLSRQSYF0.99370.6761717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:25SQQSYFVTDY0.97640.63331121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:01HVELPSQQSY0.95760.9174616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:25HVELPSQQSY0.95010.9263616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:02HVELPSQQSY0.92490.9275616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:08HVELPSQQSY0.92260.7798616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:01VELPSQQSYF0.89310.9108717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:01HVELPSQQSY0.88490.8943616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:17HVELPSQQSY0.85230.8937616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:05HVELPSQQSY0.75180.6725616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:03HVELPSQQSY0.73950.8061616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B47:01HVELPSQQSY0.54650.5947616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:03HVELPSQQSY0.49590.9323616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:01HVELPSQQSY0.29870.9026616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:18LHVELPSQQSY0.98140.675516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:03LHVELPSQQSY0.9810.7413516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B47:01LHVELPSQQSY0.96640.599516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:03LHVELPSQQSY0.8230.9463516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:01LHVELPSQQSY0.78580.8428516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:05CRLSRQSYF0.98620.9274817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:95CRLSRQSYF0.98520.5548817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:03CRLSRQSYF0.98470.8597817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:27CRLSRQSYF0.97670.9174817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:12LPSQQSYFV0.94360.7534918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:04RQSYFVTDY0.94240.62981221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:21QQSYFVTDY0.90880.74291221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:04QQSYFVTDY0.87650.61971221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:05QQSYFVTDY0.87530.72471221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:19CRLSRQSYF0.85680.5007817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:67CRLSRQSYF0.82970.8802817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:80CRLSRQSYF0.82970.8802817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:46CRLSRQSYF0.82820.7617817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:10CRLSRQSYF0.81980.8982817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:31QQSYFVTDY0.80290.74161221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:05RQSYFVTDY0.75950.70761221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:05VELPSQQSY0.72730.724716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:21VELPSQQSY0.67520.8745716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:04VELPSQQSY0.62570.8908716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:31VELPSQQSY0.59840.7451716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B39:10LPSQQSYFV0.38430.8255918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C01:30ELPSQQSYF0.0960.9233817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C12:16CRLSRQSYF0.05560.9094817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:03SRQSYFVTDY0.99690.81381121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:80SRQSYFVTDY0.98970.83781121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:67SRQSYFVTDY0.98970.83781121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:10SRQSYFVTDY0.98860.8611121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:46SRQSYFVTDY0.98510.69221121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:04SQQSYFVTDY0.95430.54551121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:21HVELPSQQSY0.92730.9217616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:07HVELPSQQSY0.92090.733616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:05SQQSYFVTDY0.9150.60981121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:05HVELPSQQSY0.90910.8779616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:03SCRLSRQSYF0.87580.8926717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:31HVELPSQQSY0.87270.8877616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:21LHVELPSQQSY0.98720.8907516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:11LPSQQSYF0.82770.713917
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:17LPSQQSYF0.82180.5141917
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:30LPSQQSYF0.82180.5141917
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:24LPSQQSYF0.78540.7095917
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04ELPSQQSY0.66320.8149816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:06ELPSQQSY0.60550.7885816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:05ELPSQQSY0.59510.7914816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:11ELPSQQSY0.49180.6531816
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:33RQSYFVTDY0.99950.61211221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:135RQSYFVTDY0.99950.61161221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:125RQSYFVTDY0.99950.61211221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:34RQSYFVTDY0.99950.61211221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:27RQSYFVTDY0.99950.61491221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:08CRLSRQSYF0.99940.6621817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:10CRLSRQSYF0.99940.7953817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:50RQSYFVTDY0.99940.59321221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:06CRLSRQSYF0.9990.625817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:27QQSYFVTDY0.99860.62611221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:33QQSYFVTDY0.99860.59831221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:34QQSYFVTDY0.99860.59831221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:125QQSYFVTDY0.99860.59831221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:135QQSYFVTDY0.99850.59971221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:50QQSYFVTDY0.99810.56821221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:24RQSYFVTDY0.9980.66631221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:12RQSYFVTDY0.99780.58621221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:13VELPSQQSY0.99640.8402716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:26VELPSQQSY0.99640.8402716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:07VELPSQQSY0.99640.8402716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04VELPSQQSY0.99410.8818716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:07VELPSQQSY0.99180.8279716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:12QQSYFVTDY0.99160.58551221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:05VELPSQQSY0.99130.865716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:35RQSYFVTDY0.99130.58471221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-A25:01ELPSQQSYF0.98940.7859817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:08VELPSQQSY0.98880.8372716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:35QQSYFVTDY0.9870.5651221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:06VELPSQQSY0.98620.8611716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:03VELPSQQSY0.98220.8554716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B78:02LPSQQSYFV0.98010.5317918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:39RQSYFVTDY0.97490.56841221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:39QQSYFVTDY0.9620.58191221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:27VELPSQQSY0.95240.8595716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:34VELPSQQSY0.95120.854716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:125VELPSQQSY0.95120.854716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:33VELPSQQSY0.95120.854716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:17CRLSRQSYF0.9450.9229817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53RQSYFVTDY0.94360.55131221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:09LPSQQSYFV0.94360.7534918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:135VELPSQQSY0.94210.8447716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:50VELPSQQSY0.90810.8817716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53QQSYFVTDY0.90090.54011221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:20QQSYFVTDY0.87170.80461221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:02CRLSRQSYF0.82970.8802817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:24VELPSQQSY0.81710.8079716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:54RQSYFVTDY0.79360.51321221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28QQSYFVTDY0.79180.80781221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:39VELPSQQSY0.79040.7777716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:20QQSYFVTDY0.78460.83531221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:35VELPSQQSY0.77760.8375716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:11VELPSQQSY0.77220.7405716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:12VELPSQQSY0.76020.845716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:20RQSYFVTDY0.75870.79251221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:20VELPSQQSY0.7340.7992716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:22CRLSRQSYF0.73350.5558817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53VELPSQQSY0.7260.8088716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28VELPSQQSY0.67760.8038716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04QQSYFVTDY0.66090.73341221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28RQSYFVTDY0.63580.79181221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B40:04VELPSQQSY0.63530.5999716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C06:08CRLSRQSYF0.61680.9793817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B67:01LPSQQSYFV0.60530.685918
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:20VELPSQQSY0.58680.8278716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:17VELPSQQSY0.46860.9464716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:54VELPSQQSY0.33790.7818716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:13VELPSQQSY0.31720.5828716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02QQSYFVTDY0.28790.78731221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02VELPSQQSY0.26780.7733716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C01:02ELPSQQSYF0.24890.8805817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02RQSYFVTDY0.22460.77381221
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C06:06CRLSRQSYF0.16510.9734817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B50:04VELPSQQSY0.08780.7102716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B50:05VELPSQQSY0.08780.7102716
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C06:02CRLSRQSYF0.07460.9841817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C06:17CRLSRQSYF0.07460.9841817
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:08SRQSYFVTDY0.99960.57761121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B27:10SRQSYFVTDY0.99960.66371121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:34SQQSYFVTDY0.99910.56551121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:125SQQSYFVTDY0.99910.56551121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:33SQQSYFVTDY0.99910.56551121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:50SQQSYFVTDY0.99890.63961121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:27SQQSYFVTDY0.99890.58561121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:135SQQSYFVTDY0.99880.56791121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:24SQQSYFVTDY0.99750.53471121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:12SQQSYFVTDY0.99620.60661121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:26VELPSQQSYF0.99490.8766717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:13VELPSQQSYF0.99490.8766717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:07VELPSQQSYF0.99490.8766717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:35SQQSYFVTDY0.99380.50651121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53SQQSYFVTDY0.99010.51151121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-C07:02SRQSYFVTDY0.98970.83781121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53VELPSQQSYF0.98720.8712717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B40:04VELPSQQSYF0.96690.6338717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:125HVELPSQQSY0.95760.9174616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:34HVELPSQQSY0.95760.9174616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:33HVELPSQQSY0.95760.9174616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:27HVELPSQQSY0.95090.9265616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:39HVELPSQQSY0.94920.8614616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:12HVELPSQQSY0.94750.8564616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:135HVELPSQQSY0.94530.9208616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:50HVELPSQQSY0.94250.9365616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:11HVELPSQQSY0.9350.8937616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:08HVELPSQQSY0.93320.8844616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04VELPSQQSYF0.92590.9231717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:43HVELPSQQSY0.92250.8857616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:20HVELPSQQSY0.92180.9087616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:20SQQSYFVTDY0.91880.68631121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02VELPSQQSYF0.91540.8086717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53HVELPSQQSY0.91510.8867616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:11HVELPSQQSY0.91480.9145616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:35HVELPSQQSY0.91280.9043616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:08VELPSQQSYF0.90020.8866717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28SQQSYFVTDY0.89620.72071121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:05VELPSQQSYF0.89310.9108717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28HVELPSQQSY0.88630.9105616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:77HVELPSQQSY0.88490.8943616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:11VELPSQQSYF0.87760.7816717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:23HVELPSQQSY0.87470.8817616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:24HVELPSQQSY0.87180.9146616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:20HVELPSQQSY0.86830.918616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:03VELPSQQSYF0.84820.9046717
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:54HVELPSQQSY0.84610.876616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:30HVELPSQQSY0.80670.8297616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:17HVELPSQQSY0.80670.8297616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:13HVELPSQQSY0.74310.6715616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:68HVELPSQQSY0.70830.6538616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-A25:01HVELPSQQSY0.70110.7839616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02HVELPSQQSY0.66710.8969616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02SQQSYFVTDY0.6450.68181121
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:11HVELPSQQSY0.51410.8758616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04HVELPSQQSY0.51140.9138616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:13HVELPSQQSY0.49590.9323616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:07HVELPSQQSY0.49590.9323616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:26HVELPSQQSY0.49590.9323616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:07HVELPSQQSY0.36630.8662616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:05HVELPSQQSY0.29870.9026616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:03HVELPSQQSY0.27610.8957616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:08HVELPSQQSY0.26860.898616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:06HVELPSQQSY0.2570.9132616
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:53LHVELPSQQSY0.99020.8491516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:20LHVELPSQQSY0.98270.8966516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B15:54LHVELPSQQSY0.97970.8285516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B35:28LHVELPSQQSY0.97550.8876516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:11LHVELPSQQSY0.96750.8558516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B48:02LHVELPSQQSY0.95950.8651516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:04LHVELPSQQSY0.88190.8563516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:13LHVELPSQQSY0.8230.9463516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:07LHVELPSQQSY0.8230.9463516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B44:26LHVELPSQQSY0.8230.9463516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:06LHVELPSQQSY0.80290.8485516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:05LHVELPSQQSY0.78580.8428516
UVRAG-RRAS2chr1175526569chr1114317401358HLA-B18:08LHVELPSQQSY0.76440.8182516

Top

Potential FusionNeoAntigen Information of UVRAG-RRAS2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
UVRAG-RRAS2_75526569_14317401.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0101SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0101SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0104SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0104SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0105SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0105SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0108SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0108SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0109SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0109SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0111SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0111SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0112SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0112SQQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0113SRQSYFVTDYDPTIE1126
UVRAG-RRAS2chr1175526569chr1114317401358DRB3-0113SQQSYFVTDYDPTIE1126

Top

Fusion breakpoint peptide structures of UVRAG-RRAS2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3533HVELPSQQSYFVTDUVRAGRRAS2chr1175526569chr1114317401358
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10540WSCRLSRQSYFVTDUVRAGRRAS2chr1175526569chr1114317401358

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of UVRAG-RRAS2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3533HVELPSQQSYFVTD-7.15543-7.26883
HLA-B14:023BVN3533HVELPSQQSYFVTD-4.77435-5.80965
HLA-B52:013W393533HVELPSQQSYFVTD-6.80875-6.92215
HLA-B52:013W393533HVELPSQQSYFVTD-4.20386-5.23916
HLA-A11:014UQ23533HVELPSQQSYFVTD-7.5194-8.5547
HLA-A11:014UQ23533HVELPSQQSYFVTD-6.9601-7.0735
HLA-A24:025HGA3533HVELPSQQSYFVTD-7.52403-7.63743
HLA-A24:025HGA3533HVELPSQQSYFVTD-5.82433-6.85963
HLA-B27:056PYJ3533HVELPSQQSYFVTD-3.28285-4.31815
HLA-B44:053DX83533HVELPSQQSYFVTD-5.91172-6.94702
HLA-B44:053DX83533HVELPSQQSYFVTD-4.24346-4.35686
HLA-B14:023BVN10540WSCRLSRQSYFVTD-7.29446-7.40786
HLA-B14:023BVN10540WSCRLSRQSYFVTD-4.22223-5.25753
HLA-B52:013W3910540WSCRLSRQSYFVTD-7.53978-7.65318
HLA-B52:013W3910540WSCRLSRQSYFVTD-3.92467-4.95997
HLA-A11:014UQ210540WSCRLSRQSYFVTD-9.11851-9.23191
HLA-A11:014UQ210540WSCRLSRQSYFVTD-6.67663-7.71193
HLA-A24:025HGA10540WSCRLSRQSYFVTD-7.32297-7.43637
HLA-A24:025HGA10540WSCRLSRQSYFVTD-6.52668-7.56198
HLA-B44:053DX810540WSCRLSRQSYFVTD-4.8579-4.9713
HLA-B44:053DX810540WSCRLSRQSYFVTD-3.64725-4.68255
HLA-A02:016TDR10540WSCRLSRQSYFVTD-7.95548-8.99078

Top

Vaccine Design for the FusionNeoAntigens of UVRAG-RRAS2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
UVRAG-RRAS2chr1175526569chr11143174011121SQQSYFVTDYCAGCAGTCCTATTTTGTAACGGATTATGAT
UVRAG-RRAS2chr1175526569chr11143174011121SRQSYFVTDYCAGCAGGCAGTCCTATTTTGTAACGGATTA
UVRAG-RRAS2chr1175526569chr11143174011221QQSYFVTDYCAGTCCTATTTTGTAACGGATTATGAT
UVRAG-RRAS2chr1175526569chr11143174011221RQSYFVTDYCAGGCAGTCCTATTTTGTAACGGATTA
UVRAG-RRAS2chr1175526569chr1114317401516LHVELPSQQSYCATGTGGAGCTGCCGTCTCAGCAGTCCTATTTT
UVRAG-RRAS2chr1175526569chr1114317401616HVELPSQQSYGTGGAGCTGCCGTCTCAGCAGTCCTATTTT
UVRAG-RRAS2chr1175526569chr1114317401716VELPSQQSYGAGCTGCCGTCTCAGCAGTCCTATTTT
UVRAG-RRAS2chr1175526569chr1114317401717SCRLSRQSYFGAGCTGCCGTCTCAGCAGGCAGTCCTATTT
UVRAG-RRAS2chr1175526569chr1114317401717VELPSQQSYFGAGCTGCCGTCTCAGCAGTCCTATTTTGTA
UVRAG-RRAS2chr1175526569chr1114317401816ELPSQQSYCTGCCGTCTCAGCAGTCCTATTTT
UVRAG-RRAS2chr1175526569chr1114317401817CRLSRQSYFCTGCCGTCTCAGCAGGCAGTCCTATTT
UVRAG-RRAS2chr1175526569chr1114317401817ELPSQQSYFCTGCCGTCTCAGCAGTCCTATTTTGTA
UVRAG-RRAS2chr1175526569chr1114317401917LPSQQSYFCCGTCTCAGCAGTCCTATTTTGTA
UVRAG-RRAS2chr1175526569chr1114317401918LPSQQSYFVCCGTCTCAGCAGTCCTATTTTGTAACG
UVRAG-RRAS2chr1175526569chr1114317401918RLSRQSYFVCCGTCTCAGCAGGCAGTCCTATTTTGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
UVRAG-RRAS2chr1175526569chr11143174011126SQQSYFVTDYDPTIECAGCAGTCCTATTTTGTAACGGATTATGATCCAACCATTGAAGAT
UVRAG-RRAS2chr1175526569chr11143174011126SRQSYFVTDYDPTIECAGCAGGCAGTCCTATTTTGTAACGGATTATGATCCAACCATTGA

Top

Information of the samples that have these potential fusion neoantigens of UVRAG-RRAS2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
HNSCUVRAG-RRAS2chr1175526569ENST00000356136chr1114317401ENST00000414023TCGA-UF-A7JV-01A
HNSCUVRAG-RRAS2chr1175526569ENST00000356136chr1114317401ENST00000537760TCGA-UF-A7JV-01A

Top

Potential target of CAR-T therapy development for UVRAG-RRAS2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to UVRAG-RRAS2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to UVRAG-RRAS2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource